RFK Jr. Explains Trump’s Math: A $600 Drug to $10 Is a ‘600% Reduction’
Published on Reflecto News | World News | Politics & Health
Health and Human Services Secretary Robert F. Kennedy Jr. has offered a revealing explanation of President Donald Trump’s distinctive approach to calculating percentages, using a prescription drug pricing example to illustrate the president’s unconventional arithmetic. Kennedy’s comments, made during a press briefing, shed light on how the Trump administration discusses its policy achievements—and why those numbers often look different from conventional calculations .
“President Trump has a different way of calculating percentages. If you have a $600 drug and you reduce it to $10, that’s a 600% reduction. He’s not wrong—if you think about it differently.” — Robert F. Kennedy Jr., Secretary of Health and Human Services
The Math: Conventional vs. Trump
Kennedy’s example highlights a fundamental difference in how percentage reductions are typically calculated versus how President Trump describes them.
| Calculation Method | Formula | Result |
|---|---|---|
| Conventional (percentage decrease) | (Original – New) / Original | ($600 – $10) / $600 = 98.3% decrease |
| Trump method | (Original – New) / New | ($600 – $10) / $10 = 5,900% reduction? |
The example in the quote references a 600% reduction, which would require a different baseline calculation .
The standard method measures the reduction relative to the original price. The alternate method measures it relative to the new price—producing dramatically different, and arguably misleading, figures.
A Pattern of Unconventional Statistics
Kennedy’s description of Trump’s “different way of calculating percentages” fits a broader pattern of the president using unconventional statistical framing to describe his policy achievements.
Trump’s approach to percentages across various domains:
| Domain | Trump’s Framing | Conventional Analysis |
|---|---|---|
| Prescription drug prices | 600% reduction (from $600 to $10) | 98% reduction |
| Trade deficits | “We’re losing $800 billion” | Gross vs. net measures differ |
| Unemployment | “The real number is much higher” | Adjusts for discouraged workers |
| Economic growth | “The best ever” | Varies by period measured |
Sources: Multiple news reports
The Drug Pricing Policy Context
The pharmaceutical industry has been a target of the Trump administration’s cost-cutting efforts, with policies aimed at reducing prescription drug prices through negotiation, competition, and price referencing.
Key drug pricing initiatives:
- Most Favored Nation (MFN) model: Basing prices on the lowest price among comparable nations
- Rebate rule: Eliminating rebates to pharmacy benefit managers
- Importation: Allowing import of drugs from Canada
- Price negotiation: Medicare negotiation for high-cost drugs
Critics have noted that while some drug prices have decreased, the overall impact on consumer out-of-pocket costs has been more modest than headline figures suggest.
The ‘Different Way of Calculating’ at Work
Kennedy’s characterization of Trump’s approach as a “different way of calculating” is diplomatic. Others have been less charitable, accusing the administration of statistical manipulation or outright dishonesty.
Reactions to Kennedy’s statement:
| Source | Reaction |
|---|---|
| Democratic lawmakers | Called it “an admission of statistical manipulation” |
| Fact-checkers | Noted that 98% and 600% cannot both be true |
| Pharmaceutical industry | Remained silent publicly |
| Conservative media | Defended as “creative framing” |
Broader Implications for Policy Communication
The incident highlights a broader tension in how the administration communicates its achievements. Supporters say Trump’s approach “cuts through bureaucratic obfuscation” and “communicates real savings to ordinary Americans.” Critics say it “undermines trust in official statistics” and “makes meaningful policy comparison impossible.”
Health policy experts note that prescription drug pricing is genuinely complex. List prices, net prices, insurance copays, and rebates vary widely, making any single percentage figure an oversimplification. However, the gap between conventional and Trumpian math is larger than can be explained by complexity alone.
What Comes Next
The administration’s drug pricing policies continue to face legal challenges, with pharmaceutical companies suing to block the Most Favored Nation model. Congressional Democrats have proposed alternative approaches, including direct government negotiation of drug prices under Medicare.
| Development | Timeline | Impact |
|---|---|---|
| MFN model litigation | Ongoing | Could reach Supreme Court |
| Congressional negotiation | 2026 | Potential new legislation |
| 2026 election | November | Could shift policy direction |
Kennedy’s explanation of Trump’s “different way of calculating” may provide a window into how the administration will frame its achievements heading into the 2026 election—using numbers that sound impressive, even if they don’t conform to conventional statistical standards.
Frequently Asked Questions (FAQs)
1. What did RFK Jr. say about Trump’s way of calculating percentages?
Kennedy stated that Trump has a “different way of calculating percentages,” using the example of a $600 drug reduced to $10 as a “600% reduction.”
2. What is the conventional calculation for a $600 to $10 price drop?
The conventional formula calculates the percentage decrease as (original minus new) divided by original: ($600 – $10) / $600 = 98.3% decrease.
3. Is a ‘600% reduction’ mathematically possible?
A reduction greater than 100% would imply a negative price—mathematically impossible for standard price decreases. The figure appears to use an unconventional baseline.
4. What drug pricing policies has the Trump administration implemented?
Key policies include the Most Favored Nation model for drug pricing, eliminating rebates to pharmacy benefit managers, allowing importation from Canada, and Medicare negotiation for high-cost drugs.
5. How has the pharmaceutical industry responded?
Pharmaceutical companies have sued to block some of these policies, particularly the Most Favored Nation model, arguing they exceed the administration’s legal authority.
6. What is the legal status of these policies?
Several policies remain tied up in litigation, with cases potentially reaching the Supreme Court depending on appellate rulings.
7. How might this affect the 2026 election?
The administration may use unconventional statistical framing to campaign on drug pricing achievements, while critics will challenge the accuracy of those figures.
Stay informed with Reflecto News – Your trusted source for breaking political, health, and economic intelligence. Subscribe for real-time updates on prescription drug policy, the 2026 election, and federal health initiatives.